Clinical Trial: Study of Fenretinide in the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: A Phase II Multicenter, Randomized, Double-Masked, Placebo-Controlled, Dose-Comparison Study of the Safety and Efficacy of Fenretinide in the Treatment of Geographic Atrophy

Brief Summary: The purpose of this phase II study is to determine the efficacy of fenretinide in the treatment of geographic atrophy (GA) in subjects with the dry form of age-related macular degeneration (AMD).

Detailed Summary:
Sponsor: Sirion Therapeutics, Inc.

Current Primary Outcome: GA lesion progression [ Time Frame: 1 year ]

Original Primary Outcome:

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Sirion Therapeutics, Inc.

Dates:
Date Received: January 30, 2007
Date Started: December 2006
Date Completion:
Last Updated: June 21, 2010
Last Verified: June 2010